Neurocentrx is a collaborative biotech company based in Edinburgh, focused on medicines to treat patients with neurological conditions. The company is developing existing drugs, in new oral delivery formats, for unmet clinical needs.
Neurocentrxs’ interests lie in psychiatric, mental health and mood disorders, neurodegenerative diseases and complex pain management in cancer and palliative care. They are developing oral ketamine formulations for clinical trials in these areas.
Ketamine has been shown by others to be useful in treating Depression. Ketamine seems to act quickly in responding patients. This is key, as most antidepressants take many weeks to work, or to fail. Long-term effects of Ketamine and its mechanism of action are not yet fully understood, but much research worldwide continues in these areas.
|Investment Portfolio||Fund Investment|